Key Takeaways The release of these FAQs along with guidance from other states signals increasing regulation (and presumably enforcement) of GLP-1 compounding
In younger people with longer duration of disease (such as those with youth-onset type 1 diabetes), more frequent lipid profiles may be reasonable
To access our educational resources & content, become a transparent member today
This helps support the site and allows us to continue creating practical resources
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) Diabet Med
As one of the most extensively studied GLP-1 receptor agonists, Semaglutide has been the subject of multiple large-scale clinical trial programs (SUSTAIN, STEP, SELECT, PIONEER) investigating its effects on glucose homeostasis, body weight regulation, and cardiovascular outcomes
